Taysha Gene Therapies (TSHA) Cash & Equivalents (2020 - 2026)

Taysha Gene Therapies has reported Cash & Equivalents for 7 years, with the latest figure at $276.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 137.24% year-over-year to $276.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $276.6 million (up 137.24% YoY) and the FY2025 annual result came in at $319.8 million, up 129.99% from the prior year.
• Cash & Equivalents slipped to $276.6 million in Q1 2026 per TSHA's latest filing, from $319.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $319.8 million in Q4 2025 and troughed at $36.9 million in Q3 2022.
• A 5-year average of $158.5 million and a median of $141.5 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slumped 80.7% in 2022, then surged 344.68% in 2023.
• Over 5 years, Cash & Equivalents stood at $36.9 million in 2022, then soared by 289.63% to $143.9 million in 2023, then declined by 3.41% to $139.0 million in 2024, then surged by 129.99% to $319.8 million in 2025, then declined by 13.5% to $276.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $276.6 million, $319.8 million, and $297.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.